MetaCap

Perspective Therapeutics (CATX) vs NeOnc Technologies (NTHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeOnc Technologies (NTHI) has outperformed Perspective Therapeutics (CATX) over the past year, losing 46.2% versus a loss of 63.9%. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $90.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%NTHI-46.25%
+182%+53%-76%
Nov 21, 20251 yearNov 20, 2026
CATX-65.74%NTHI-80.97%
+169%+37%-96%
Mar 24, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus NTHI key metrics
MetricCATXNTHI
Share price$0.7538$3.15
Market cap$91.03M$90.88M
1-day change-3.85%-9.48%
YTD return-72.59%-61.91%
1-year return-63.93%-46.25%
5-year return-84.62%—
EPS (TTM)$-1.25$-1.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$39.99K
Revenue growth (YoY)—-51.82%
Net income (latest FY)$-103.12M$-62.15M
Operating margin—-145637.52%
Net margin—-155404.38%
52-week high$6.16$11.38
52-week low$0.73$2.50
Distance from 52-week high-87.76%-72.31%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1188.14%+439.68%
Average volume2.70M187.23K
Shares outstanding120.76M28.85M
Employees1635
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NTHI has outperformed CATX by 17.7 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About NeOnc Technologies

NTHI stock →

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CATX vs NTHI FAQ

Which is bigger, Perspective Therapeutics or NeOnc Technologies?

Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $90.88M for NeOnc Technologies (NTHI).

Which stock has performed better over the past year, CATX or NTHI?

NTHI returned -46.25% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and NeOnc Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons